文献速递肿瘤 PET/CT

靶向胃肠道肿瘤CLDN18.2的新型纳米抗体PET探针[68Ga]Ga-PMD22的合成、临床前评价及初步临床转化

Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-06-27

本研究合成靶向紧密连接蛋白18.2(CLDN18.2)的纳米抗体探针[68Ga]Ga-PMD22,在细胞和荷瘤鼠中验证结合与显像性能,并在5例胃肠道肿瘤患者中评估有效剂量、在16例患者中与[18F]FDG PET/CT头对头显像并与病理免疫组化对比,初步证明其安全有效。

要点

  • [68Ga]Ga-PMD22对CLDN18.2阳性细胞结合能力高于对照细胞(p < 0.001)。
  • 5例患者中有效剂量为1.68E-02 ± 1.45E-02 mSv/MBq。
  • CLDN18.2免疫组化与[68Ga]Ga-PMD22的SUVmax/BKGstomach高度相关(rs = 0.848,p < 0.01)。

核心结论

  • [68Ga]Ga-PMD22被初步证明安全有效,可显示CLDN18.2阳性胃肠道肿瘤,为该探针的临床转化提供依据。

研究设计与样本

  • 临床前细胞结合实验与荷瘤鼠microPET/CT显像,随后在5例胃肠道肿瘤患者中评估有效剂量,并在16例胃肠道肿瘤患者中头对头进行[68Ga]Ga-PMD22与[18F]FDG PET/CT显像,取病理组织行CLDN18.2免疫组化染色并与PET/CT结果对比分析。

主要发现

  • 细胞结合实验显示[68Ga]Ga-PMD22对AGSCLDN18.2和BGC823CLDN18.2细胞的结合能力高于对AGS和BGC823细胞(p < 0.001);microPET/CT显示[68Ga]Ga-PMD22在AGSCLDN18.2和BGC823CLDN18.2肿瘤中快速聚集,肿瘤与本底对比清晰;5例患者中有效剂量为1.68E-02 ± 1.45E-02 mSv/MBq;CLDN18.2免疫组化结果与[68Ga]Ga-PMD22的SUVmax/BKGstomach高度相关(rs = 0.848,p < 0.01)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Claudin18.2 (CLDN18.2) is a novel target for diagnosis and therapy of gastrointestinal cancer. This study aimed to evaluate the safety and feasibility of a novel CLDN18.2-targeted nanobody, PMD22, labeled with gallium-68 ([68Ga]Ga), for detecting CLDN18.2 expression in patients with gastrointestinal cancer using PET/CT imaging. METHODS: [68Ga]Ga-PMD22 was synthesized based on the nanobody, and its cell binding properties were assayed. Preclinical pharmacokinetics were determined in CLDN18.2-positive xenografts using microPET/CT. Effective dosimetry of [68Ga]Ga-PMD22 was evaluated in 5 gastrointestinal cancer patients, and PET/CT imaging of [68Ga]Ga-PMD22 and [18F]FDG were performed head-to-head in 16 gastrointestinal cancer patients. Pathological tissues were obtained for CLDN18.2 immunohistochemical (IHC) staining and comparative analysis with PET/CT findings. RESULTS: Cell binding assay showed that [68Ga]Ga-PMD22 had a higher binding ability to AGSCLDN18.2 and BGC823CLDN18.2 cells than to AGS and BGC823 cells (p < 0.001). MicroPET/CT images showed that [68Ga]Ga-PMD22 rapidly accumulated in AGSCLDN18.2 and BGC823CLDN18.2 tumors, and high contrast tumor to background imaging was clearly observed. In the pilot study, the effective dose of [68Ga]Ga-PMD22 was 1.68E-02 ± 1.45E-02 mSv/MBq, and the CLDN18.2 IHC staining result was highly correlated with the SUVmax/BKGstomach of [68Ga]Ga-PMD22 (rs = 0.848, p < 0.01). CONCLUSION: A novel [68Ga]Ga-labeled nanobody probe targeting CLDN18.2, [68Ga]Ga-PMD22, was established and preliminarily proved to be safe and effective in revealing CLDN18.2-positive gastrointestinal cancer, providing a basis for the clinical translation of the agent. CLINICAL TRIAL REGISTRATION: This study was registered on the ClinicalTrials.gov (NCT05937919).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang R, Bai Z, Zhong W, et al. Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 38926162. doi:10.1007/s00259-024-06808-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。